NASDAQ:DICE DICE Therapeutics (DICE) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$47.55▼$47.5550-Day Range$46.62▼$47.5552-Week Range$15.08▼$47.90VolumeN/AAverage Volume1.03 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice Target$62.40 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About DICE Therapeutics (NASDAQ:DICE) StockDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More DICE Stock News HeadlinesSeptember 11, 2023 | markets.businessinsider.comWells Fargo Sticks to Their Hold Rating for Incyte (INCY)August 9, 2023 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About DICE TherapeuticsSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 9, 2023 | finanznachrichten.deEli Lilly and Company: Lilly Completes Acquisition of DICE TherapeuticsAugust 9, 2023 | msn.comHC Wainwright & Co. Reiterates DICE Therapeutics (DICE) Neutral RecommendationAugust 9, 2023 | finance.yahoo.comLilly Completes Acquisition of DICE TherapeuticsAugust 8, 2023 | finanznachrichten.deEli Lilly and Company: Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsAugust 8, 2023 | markets.businessinsider.comLilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 25, 2023 | markets.businessinsider.comLilly Extends Tender Offer To Acquire DICEJuly 25, 2023 | finance.yahoo.comLilly Announces Extension of Tender Offer to Acquire DICEJuly 12, 2023 | msn.comDrugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts sayJuly 6, 2023 | msn.comDICE Therapeutics (DICE) Price Target Decreased by 19.70% to 50.21June 27, 2023 | finance.yahoo.comMergers Are Down, but These 2 Sectors Are BoomingJune 26, 2023 | benzinga.comShort Volatility Alert: Dice TherapeuticsJune 26, 2023 | msn.comNeedham Downgrades DICE Therapeutics (DICE)June 26, 2023 | benzinga.comNeedham Downgrades DICE Therapeutics to HoldJune 21, 2023 | markets.businessinsider.comDice Therapeutics (DICE) Receives a New Rating from a Top AnalystJune 21, 2023 | msn.comCantor Fitzgerald Downgrades DICE Therapeutics (DICE)June 21, 2023 | msn.comCanaccord Genuity Downgrades DICE Therapeutics (DICE)June 20, 2023 | msn.comAnalyst Expectations for DICE Therapeutics's FutureJune 20, 2023 | wsj.comThe Lilly-Dice Biotech Buyout Deals Short Sellers Another BlowJune 20, 2023 | fool.comEli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to KnowJune 20, 2023 | markets.businessinsider.comWhy DICE Therapeutics Stock Is Soaring TuesdayJune 20, 2023 | finance.yahoo.comLilly Decides to Roll the Dice: My Plan for the Stock NowJune 20, 2023 | finance.yahoo.comPayPal-KKR deal, Alibaba shares fall, Eli Lilly-Dice Therapeutics deal: Trending tickersJune 20, 2023 | finance.yahoo.comDice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly BuyoutSee More Headlines Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DICE Company Calendar Last Earnings8/08/2023Today9/28/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DICE CUSIPN/A CIK1645569 Webwww.dicemolecules.com Phone650-566-1420FaxN/AEmployees71Year FoundedN/APrice Target and Rating Average Stock Price Forecast$62.40 High Stock Price Forecast$77.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+31.2%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.01% Return on Assets-20.79% Debt Debt-to-Equity RatioN/A Current Ratio25.88 Quick Ratio32.44 Sales & Book Value Annual Sales$1.13 million Price / Sales2,008.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.86 per share Price / Book4.38Miscellaneous Outstanding Shares47,731,000Free Float45,392,000Market Cap$2.27 billion OptionableNot Optionable Beta1.03 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. J. Kevin Judice Ph.D. (Age 59)Founder, CEO & Director Comp: $840kMr. Scott RobertsonChief Bus. & Financial OfficerDr. Timothy Lu M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $700kDr. John R. Jacobsen Ph.D. (Age 54)Chief Scientific Officer Ms. Mary Riley J.D.Gen. CounselMr. Venkat Thalladi Ph.D.Sr. VP of CMCMr. Paul FathereeSr. VP of Medicinal ChemistryMore ExecutivesKey CompetitorsXenon PharmaceuticalsNASDAQ:XENEZai LabNASDAQ:ZLABProtagonist TherapeuticsNASDAQ:PTGXREGENXBIONASDAQ:RGNXOmniAbNASDAQ:OABIView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemSold 2,308 shares on 8/21/2023Ownership: 0.080%Wells Fargo & Company MNBought 9,856 shares on 8/15/2023Ownership: 0.034%Boothbay Fund Management LLCBought 8,800 shares on 8/15/2023Ownership: 0.000%Westchester Capital Management LLCBought 8,400 shares on 8/15/2023Ownership: 0.000%Royal Bank of CanadaBought 703 shares on 8/15/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions DICE Stock - Frequently Asked Questions Should I buy or sell DICE Therapeutics stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DICE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DICE, but not buy additional shares or sell existing shares. View DICE analyst ratings or view top-rated stocks. What is DICE Therapeutics' stock price forecast for 2023? 13 brokers have issued 1-year target prices for DICE Therapeutics' stock. Their DICE share price forecasts range from $48.00 to $77.00. On average, they predict the company's stock price to reach $62.40 in the next year. This suggests a possible upside of 31.2% from the stock's current price. View analysts price targets for DICE or view top-rated stocks among Wall Street analysts. When is DICE Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our DICE earnings forecast. How were DICE Therapeutics' earnings last quarter? DICE Therapeutics, Inc. (NASDAQ:DICE) posted its earnings results on Tuesday, August, 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.09. What ETFs hold DICE Therapeutics' stock? ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), AltShares Merger Arbitrage ETF (ARB), First Trust Merger Arbitrage ETF (MARB), ProShares Merger ETF (MRGR), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and AltShares Event-Driven ET (EVNT). When did DICE Therapeutics IPO? (DICE) raised $160 million in an initial public offering on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share. What is DICE Therapeutics' stock symbol? DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE." Who are DICE Therapeutics' major shareholders? DICE Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.06%), Alpine Associates Management Inc. (4.43%), Driehaus Capital Management LLC (4.27%), Braidwell LP (2.16%), KRYGER CAPITAL Ltd (1.85%) and State Street Corp (1.75%). Insiders that own company stock include James Paul Scopa, John R Jacobsen, Kevin Judice, Lu Timothy, Northpond Ventures Gp, Llc, Ra Capital Management, LP, Richard H Scheller and Scott M Robertson. View institutional ownership trends. What is DICE Therapeutics' stock price today? One share of DICE stock can currently be purchased for approximately $47.55. How much money does DICE Therapeutics make? DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $2.27 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. How can I contact DICE Therapeutics? DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com. This page (NASDAQ:DICE) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.